Interferon alfa-2a: Difference between revisions
No edit summary |
|||
| Line 35: | Line 35: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Antiviral]] | ||
[[Category:Wikinfect]] | [[Category:Wikinfect]] | ||
Revision as of 14:29, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.
Category
Antiviral
US Brand Names
ROFERON-A®,PEGASYS®,GUNA-INF ALPHA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
The mechanism by which Interferon alfa-2a, recombinant, or any other interferon, exerts antitumor or antiviral activity is not clearly understood. However, it is believed that direct antiproliferative action against tumor cells, inhibition of virus replication and modulation of the host immune response play important roles in antitumor and antiviral activity.